Table 1. Association between clinicopathological variables and immunohistochemical expression of ANO1, β-catenin, cyclin D1, MMP9, snail, and E-cadherin in breast carcinomas.

Characteristics		No.	ANO1		β-catenin		Cyclin D1		MMP9		Snail		E-cadherin
			Positive	P	Positive	P	Positive	P	Positive	P	Positive	P	Negative	P
Age, y	<50	98	51 (52%)	0.726	37 (38%)	0.888	41 (42%)	0.968	60 (61%)	0.275	40 (41%)	0.737	27 (28)	0.032
	≥50	41	20 (49%)		16 (39%)		17 (41%)		21 (51%)		18 (44%)		19 (46%)
TNM stage	I	25	15 (60%)	0.251	10 (40%)	0.623	11 (44%)	0.965	11 (44%)	0.275	7 (28%)	0.229	6 (24%)	0.439
	II	95	44 (46%)		34 (36%)		39 (41%)		58 (61%)		41 (43%)		32 (34%)
	III and IV	19	12 (63%)		9 (47%)		8 (42%)		12 (63%)		10 (53%)		8 (42%)
T stage	1	37	24 (65%)	0.107	15 (41%)	0.910	16 (43%)	0.862	20 (54%)	0.201	15 (41%)	0.975	12 (32%)	0.995
	2	93	44 (47%)		35 (38%)		39 (42%)		58 (62%)		39 (42%)		31 (33%)
	3 and 4	9	3 (33%)		3 (33%)		3 (33%)		3 (33%)		4 (44%)		3 (33%)
Lymph node metastasis	Absence	77	38 (49%)	0.650	27 (35%)	0.407	31 (40%)	0.696	39 (51%)	0.042	23 (30%)	0.002	22 (29%)	0.207
	Presence	62	33 (53%)		26 (42%)		27 (44%)		42 (68%)		35 (56%)		24 (39%)
Distant metastatic relapse	Absence	104	43 (41%)	<0.001	35 (34%)	0.061	36 (35%)	0.003	56 (54%)	0.068	38 (37%)	0.032	28 (27%)	0.008
	Presence	35	28 (80%)		18 (51%)		22 (63%)		25 (71%)		20 (57%)		18 (51%)
Latent bone metastasis	Absence	129	62 (48%)	0.011	49 (38%)	0.899	50 (39%)	0.011	74 (57%)	0.435	53 (41%)	0.582	39 (30%)	0.010
	Presence	10	9 (90%)		4 (40%)		8 (80%)		4 (40%)		5 (50%)		7 (70%)
Histologic type	NST	131	67 (51%)	0.950	53 (40%)	0.022	54 (41%)	0.625	79 (60%)	0.049	57 (44%)	0.084	38 (29%)	<0.001
	Lobular	8	4 (50%)		0 (0%)		4 (50%)		2 (25%)		1 (13%)		8 (100%)
Mitoses/10 HPF	0–9	88	41 (47%)	0.375	25 (28%)	0.008	36 (41%)	0.096	41 (47%)	<0.001	34 (39%)	0.115	29 (33%)	0.611
	10–19	26	15 (58%)		15 (58%)		15 (58%)		19 (73%)		9 (35%)		7 (27%)
	>19	25	15 (60%)		13 (52%)		7 (28%)		21 (84%)		15 (60%)		10 (40%)
Histologic grade	1	48	23 (48%)	0.412	13 (27%)	0.022	20 (42%)	0.365	19 (40%)	<0.001	15 (31%)	0.11	14 (29%)	0.720
	2	62	30 (48%)		23 (37%)		29 (47%)		37 (60%)		27 (44%)		21 (34%)
	3	29	18 (62%)		17 (59%)		9 (31%)		25 (86%)		16 (55%)		11 (38%)
HER2	Negative	95	44 (46%)	0.099	33 (35%)	0.226	35 (37%)	0.086	54 (57%)	0.615	40 (42%)	0.894	30 (32%)	0.577
	Positive	44	27 (61%)		20 (45%)		25 (57%)		27 (61%)		18 (41%)		16 (36%)
ER	Negative	62	32 (52%)	0.910	28 (45%)	0.126	16 (26%)	<0.001	38 (61%)	0.517	26 (42%)	0.964	20 (32%)	0.851
	Positive	77	39 (51%)		25 (32%)		42 (55%)		43 (56%)		32 (42%)		26 (34%)
PR	Negative	58	32 (55%)	0.414	22 (38%)	0.967	14 (24%)	<0.001	32 (55%)	0.530	27 (47%)	0.329	22 (38%)	0.305
	Positive	81	39 (48%)		31 (38%)		44 (54%)		49 (60%)		31 (38%)		24 (30%)
E-cadherin	Negative	46	32 (70%)	0.002	17 (37%)	0.841	21 (46%)	0.509	25 (54%)	0.509	16 (35%)	0.243
	Positive	93	39 (42%)		36 (39%)		37 (40%)		56 (60%)		42 (45%)
Snail	Negative	81	32 (40%)	0.001	26 (32%)	0.084	34 (42%)	0.944	35 (43%)	<0.001
	Positive	58	39 (67%)		27 (47%)		24 (41%)		46 (79%)
MMP9	Negative	58	23 (40%)	0.023	10 (17%)	<0.001	15 (26%)	0.001
	Positive	81	48 (59%)		43 (53%)		43 (53%)
Cyclin D1	Negative	81	33 (41%)	0.004	24 (30%)	0.015
	Positive	58	38 (66%)		29 (50%)
β-catenin	Negative	86	35 (41%)	0.002
	Positive	53	36 (68%)

NST, invasive carcinoma of no special type; HPF, high-power fields; ER, estrogen receptor; PR, progesterone receptor.